Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics (CRSP) is a clinical-stage biopharmaceutical leader pioneering CRISPR/Cas9 gene editing therapies for serious diseases. This page aggregates official announcements, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and researchers will find timely updates on therapeutic programs targeting hemoglobinopathies, oncology, and autoimmune disorders. Track regulatory milestones, partnership announcements with industry leaders, and financial performance reports. All content is curated to meet investor needs for decision-making clarity.
Key updates include progress in allogeneic CAR-T cell therapies, hemoglobinopathy treatment approvals, and manufacturing scale-up initiatives. Bookmark this page for structured access to CRISPR Therapeutics' latest scientific advancements and business developments.
CRISPR Therapeutics presented new preclinical data at the ASGCT meeting, highlighting in vivo gene editing using lipid nanoparticles for ocular and liver targets. The company introduced two new programs, CTX340 and CTX450, demonstrating promising results for refractory hypertension and acute hepatic porphyria. Clinical trials for these programs are set to begin in the second half of 2025. Additionally, the company showcased its ability to edit genes in the eye for potential glaucoma treatments.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
